The oncologist Journal

•  
• Identity
•  
• Other
•  
• View All
•  

Identity

International Standard Serial Number (ISSN)

• 1549-490X

Other

publication venue for

• Phase II Study of Sorafenib and Bortezomib for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma..  :-. 2015